atrial natriuretic factor acetate

ANP (1-11), rat acetate (Atrial natriuretic factor (1-11) acetate) 是心房利钠因子之一，是 CRF 刺激的 ACTH 分泌的抑制剂。

Human growth hormone-releasing factor acetate 是一种下丘脑多肽，通过与垂体前叶细胞上的 GHRH 受体 (GHRHR) 结合来刺激 GH 的产生和释放。

C-Type Natriuretic Peptide (CNP) (1-22), human acetate 是一种利钠肽受体 B (NPR-B) 的激动剂，一种内皮衍生的松弛剂和生长抑制因子。 C-Type Natriuretic Peptide (CNP) (1-22), human acetate 抑制由组胺和 5-HT 或直接由毛喉素刺激的 cAMP 合成。

Corticotropin-releasing factor (human) acetate 刺激垂体前叶合成和分泌促肾上腺皮质激素。

α-Factor Mating Pheromone, yeast acetate (Mating Factor α acetate)(59401-28-4 free base) 是由酿酒酵母α细胞分泌的13个氨基酸的肽。

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate 是颗粒鸟苷酸环化酶的刺激剂，已被发现通过增加环鸟苷单磷酸的合成来保护分离的心肌细胞免受复氧诱导的高收缩。Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate 也有助于在反复运动期间刺激脂解，并在运动期间控制脂解。

Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide hormone synthesized by ventricular cardiomyocytes as a result of myocardial cell stretching (cardiomyocyte distension)[1].

Atrial natriuretic peptide (3-28) (human) 是由心房心肌细胞合成并分泌的肽类激素，主要在调节血压、体液平衡及电解质稳态方面发挥作用。

Atrial natriuretic factor (1-28) from both human and porcine sources is a powerful suppressor of pro-opiomelanocortin (POMC) mRNA, while it only has a modest inhibition effect on βEP-LI release.

Atrial Natriuretic Peptide (1-28), rat is the major circulating form of ANP in rats.

BNP-32（Brain natriuretic peptide-32）是心血管激素前体proBNP的肽段，能够结合大鼠血管平滑肌上的利钠肽受体（IC50 = 7.3 nM），并在同样的细胞中促进cGMP积累（EC50 = 170 nM）。BNP-32还能使经去甲肾上腺素预收缩的孤立大鼠主动脉条带松弛（EC50 = 6.7 nM），当以3 µg/kg的剂量给药时，能增加大鼠的尿量和尿液电解质排泄，并诱导低血压。

Human CRF acetate is a chemical compound that effectively stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

Prepro-Atrial Natriuretic Factor (26-55) (human) 为促进肾皮质与髓质循环GMP水平上升的多肽，同时也增强肾腺苷酸环化酶的活性。

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) that exerts endocrine effects on fluid homeostasis and blood pressure. Atrial Natriuretic Peptide holds promise for cardiovascular diseases research.

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA), is the primary circulating form of ANP in rats and significantly inhibits Ang II-stimulated secretion of endothelin-1.